From: powerallpharmacy@gmail.com 
  
 RITALIN€€ 
 (methylphenidate hydrochloride) USP Tablets 
  
 RITALIN-SR€€ 
 (methylphenidate hydrochloride) USP Sustained-Release Tablets 
  
 DESCRIPTION 
 Ritalin hydrochloride, methylphenidate hydrochloride USP, is a mild central 
 nervous system (CNS) stimulant, available as tablets of 5, 10, and 20 mg for 
 oral administration; Ritalin-SR is available as sustained-release tablets of 
 20 mg for oral 
 administration. Methylphenidate hydrochloride is methyl €€-phenyl-2- 
 piperidine 
 acetate hydrochloride, 
  
 Methylphenidate hydrochloride USP is a white, odorless, fine crystalline 
 powder. Its solutions are acid to litmus. It is freely soluble in water and 
 in 
 methanol, soluble in alcohol, and slightly soluble in chloroform and in 
 acetone. Its molecular weight 
 is 269.77. 
  
 Inactive Ingredients. Ritalin tablets: D&C Yellow No. 10 (5-mg and 20-mg 
 tablets), FD&C Green No. 3 (10-mg tablets), lactose, magnesium stearate, 
 polyethylene glycol, starch (5-mg and 10-mg tablets), sucrose, talc, and 
 tragacanth (20-mg tablets). 
  
 Ritalin-SR tablets: Cellulose compounds, cetostearyl alcohol, lactose, 
 magnesium stearate, mineral oil, povidone, titanium dioxide, and zein. 
  
 INDICATIONS 
 Attention Deficit Disorders, Narcolepsy 
 Attention Deficit Disorders (previously known as Minimal Brain Dysfunction 
 in 
 Children). Other terms being used to describe the behavioral syndrome below 
 include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral 
 Dysfunction, Minor 
 Cerebral Dysfunction. 
  
 Ritalin is indicated as an integral part of a total treatment program which 
 typically includes other remedial measures (psychological, educational, 
 social) for a stabilizing effect in children with a behavioral syndrome 
 characterized by the following 
 group of developmentally inappropriate symptoms: moderate-to-severe 
 distractibility, short attention span, hyperactivity, emotional lability, 
 and 
 impulsivity. The diagnosis of this syndrome should not be made with finality 
 when these symptoms are only of 
 comparatively recent origin. Nonlocalizing (soft) neurological signs, 
 learning 
 disability, and abnormal EEG may or may not be present, and a diagnosis of 
 central nervous system dysfunction may or may not be warranted. 
  
 DOSAGE AND ADMINISTRATION 
 Dosage should be individualized according to the needs and responses of the 
 patient. 
  
 Adults 
 Tablets: Administer in divided doses 2 or 3 times daily, preferably 30 to 45 
 minutes before meals. Average dosage is 20 to 30 mg daily. Some patients may 
 require 40 to 60 mg daily. In others, 10 to 15 mg daily will be adequate. 
 Patients who are unable to 
 sleep if medication is taken late in the day should take the last dose 
 before 
 6 p.m. 
  
 SR Tablets: Ritalin-SR tablets have a duration of action of approximately 8 
 hours. Therefore, Ritalin-SR tablets may be used in place of Ritalin tablets 
 when the 8-hour dosage of Ritalin-SR corresponds to the titrated 8-hour 
 dosage 
 of Ritalin. Ritalin-SR 
 tablets must be swallowed whole and never crushed or chewed. 
  
 Children (6 Years and Over) 
 Ritalin should be initiated in small doses, with gradual weekly increments. 
 Daily dosage above 60 mg is not recommended. 
  
 If improvement is not observed after appropriate dosage adjustment over a 
 1-month period, the drug should be discontinued. 
  
 Tablets: Start with 5 mg twice daily (before breakfast and lunch) with 
 gradual 
 increments of 5 to 10 mg weekly. 
  
 SR Tablets: Ritalin-SR tablets have a duration of action of approximately 8 
 hours. Therefore, Ritalin-SR tablets may be used in place of Ritalin tablets 
 when the 8-hour dosage of Ritalin-SR corresponds to the titrated 8-hour 
 dosage 
 of Ritalin. Ritalin-SR 
 tablets must be swallowed whole and never crushed or chewed. 
  
 If paradoxical aggravation of symptoms or other adverse effects occur, 
 reduce 
 dosage, or, if necessary, discontinue the drug. 
  
 Ritalin should be periodically discontinued to assess the child's condition. 
 Improvement may be sustained when the drug is either temporarily or 
 permanently discontinued. 
  
 Drug treatment should not and need not be indefinite and usually may be 
 discontinued after puberty. 
  
 Store at 25€€C (77€€F); excursions permitted to 15€€C-30€€C (59€€F-86€€F) 
 [see 
 USP Controlled Room Temperature]. Protect from moisture. 
  
 For More Details: 
 https://www.powerallpharmacy.ca/index.php?main_page=product_info 
 cPath=1_9&products_id=102 
 Whatsapp: +1 (336) 267-4575 
  
 --- SoupGate-Win32 v1.05 
  * Origin: you cannot sedate... all the things you hate (1:229/2)